Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study

Journal of Hypertension

Volumn 27, Issue 7, 2009, Pages 1360-1369

  Sleight, Peter ^a   Redon, Josep ^b   Verdecchia, Paolo ^c   Mancia, Giuseppe ^d   Gao, Peggy ^e   Fagard, Robert ^f   Schumacher, Helmut ^g   Weber, Michael ^h   Böhm, Michael ⁱ   Williams, Bryan ^j   Pogue, Janice ^e   Koon, Teo ^e   Yusuf, Salim ^e  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

^e MCMASTER UNIVERSITY   (Canada)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^h SUNY Downstate Medical Center   (United States)

ⁱ SAARLAND UNIVERSITY   (Germany)

^j UNIVERSITY OF LEICESTER   (United Kingdom)

more..

Author keywords

Blood pressure lowering; Death; Dialysis; High risk patients; Hypertension guidelines; J curve; Mortality; Myocardial infarction; Stroke

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RAMIPRIL; TELMISARTAN;

ADULT; AGED; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; STROKE; SYSTOLIC BLOOD PRESSURE;

EID: 67649790352     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32832d7370     Document Type: Article

References (20)

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
2. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al., Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet 2007; 370:1829-1839.
3. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al.Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335:827-838.
4. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
6. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A, FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens2005; 23:2157-2172.
7. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041.
8. Fox KM, European trial on Reduction of cardiac events with Perindopril in stable coronary Artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782-788.
9. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist versus a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805-2816.
10. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370:829-840.
11. Messerli FH, Mancia GC, Conti R, Hewkin AC, Kupfer S, Champion A, et al.Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Int Med 2006; 144:884-893.
12. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
13. El Assaad M, Topouchian J, Le Dudal K, Labaki G, Asmar R. Validation of the Omron M5-I blood pressure device according to the international validation protocol. J Hypertens 2003; 21 (Suppl 4):S23.
14. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R. Underestimation of risk associations due to regression dilution in longterm follow-up of prospective studies. Am J Epidemiol 1999; 150:341- 353.
15. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, et al.Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355:865-872.
16. Boutitie F, Gueyffier F, Pocock S, Fagard R, Boissel JP, for the INDANA Project. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individualpatient data. Ann Intern Med 2002; 136:438-448.
17. Sleight P. Blood pressures, hearts, and U-shaped curves. Lancet 1988; 1:235.
18. Jamerson K, Weber MA, Bakris GL, Dahlö f B, Pitt B, Shi V, et al., for the ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med2008; 359:2417-2428.
19. Hansson L, Zanchetti A, Carruthers SG, Dahlö f B, Elmfeldt D, Julius S, et al.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762.
20. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009; 27:923-934.